Treatment of gastrointestinal stromal tumor with imatinib mesylate: A retrospective single-center experience in heidelberg

Digestive Diseases

Volumn 24, Issue 1-2, 2006, Pages 207-211

  Kasper, Bernd ^a   Kallinowski, Birgit ^a   Herrmann, Thomas ^a   Lehnert, Thomas ^b   Mechtersheimer, Gunhild ^a   Geer, Thomas ^c   Ho, Anthony D ^a   Egerer, Gerlinde ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c Diakonie Krankenhaus   (Germany)

Author keywords

Gastrointestinal stromal tumor; Imatinib mesylate; Neoadjuvant; Palliative

Indexed keywords

ABELSON KINASE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GERMANY; HUMAN; MALE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SKIN CRUST; SKIN TOXICITY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; GERMANY; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646722670     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090322     Document Type: Article

References (22)

1. Mietinnen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220.
2. Mechtersheimer G, Lehnert T, Penzel R, Joos S, Egerer G, Otto HF: Gastrointestinale Stromatumoren. Pathologe 2003;24:182-191.
3. DeMatteo R, Lewis J, Leung D, Mudan S, Woodruff J, Brennan M: Two hundred gastrointestinal stromal tumors, recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
4. Flugstad DL, Wilke CP, McNutt MA, Welk RA, Hart MJ, McQuinn WC: Importance of surgical resection in the successful management of soft tissue sarcomas. Arch Surg 1999;134:856-861.
5. Dirix LY, van Oosterom AT: Soft tissue sarcomas in adults. Curr Opin Oncol 1999;11:285-295.
6. Verweij J, Mouridson HAT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT, van Glabbeke M, Tursz T: The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201.
7. Benjamin RS, Legha SS, Patel SR, Nicaise C: Single agent ifosfamide studies in sarcomas of soft tissue and bone: the MD Anderson experience. Cancer Chemother Pharmacol 1993;31:174-179.
8. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al: Doxombicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
9. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1999;154:53-60.
10. Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R: Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 2004;444:108-118.
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001;344:1084-1086.
12. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: Kit activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
13. Andersson J, Sjögren H, Meis-Kindblom J, Stenman G, Aman P, Kindblom LG: The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15-22.
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker BJ, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
15. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001;358:1421-1423.
16. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:462-463.
17. Therasse P, Arbruck SG, Eisenhauser EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
18. Graadt van Roggen JF, Van Velthuysen MLF, Hogendoorn PCW: The histopathological differential diagnosis of gastrointestinal stromal tumors. J Clin Pathol 2001;54:96-103.
19. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
20. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PCW, di Paola ED, Brown M, Nielsen OS: Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but dose not yield responses in other soft-tissue sarcomas that are unselected for molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
21. Buemming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, Waengberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B: Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003;89:460-464.
22. Fletcher JA, Corless CL, Dimitrijevic S, von Mehren M, Eisenberg B, Joensuu H, Fletcher CDM, Blanke C, Demetri GD, Heinrich MC: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003;22:815.